Abstract: One purpose of clinical neurochemistry has been to indicate " activities'' of catecholamine systems, by assaying levels of the effector compounds or their metabolites in body fluids such as plasma, cerebrospinal fluid, urine, or microdialysate. This review discusses a new purpose: relating specific catecholaminergic pheno types to neurogenetic disorders. Distinctive catechol amine patterns in several neurogenetic conditions reflect enzyme deficiencies as direct or indirect effects of gene mutations. These neurochemical patterns can provide potentially important clues to the diagnosis, treatment, and pathophysiology of neurogenetic disorders. Linking genetic abnormalities with molecular mechanisms and clinical manifestations of disease represents a useful new direction in clinical neurochemistry.
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Until recently, clinical catecholamine neurochemis try has been used mainly to examine release of cate cholamines as effector chemicals in the brain and pe riphery, in order to indicate " activities5' of central or peripheral neuronal systems. The development of assay techniques for simultaneous measurements of concen trations of catecholamines, the catecholamine precur sor DOPA, and catecholamine metabolites, such as dihydroxyphenylglycol (D H P G ), dihydroxyphenylacetic acid (DOPAC), methoxyhydroxyphenylglycol (MHPG), homo vanillic acid (H V A ), metanephrine (MN), and normetanephrine (N M N ), has enabled de tailed and comprehensive assessments of specific as pects of catecholaminergic function, including release, neuronal and extraneuronal uptake and metabolism, turnover, and synthesis (Eisenhofer et al, 1992) .
The availability of these simultaneous assays has led to a novel application of clinical catecholamine neurochemistry: the delineation of neurochemical pat terns associated with specific genetic abnormalities.
These patterns can provide potentially important clues to the diagnosis, treatment, and pathophysiology of neurogenetic disorders. This brief review summarizes what has been learned so far from this new approach.
Understanding the clinical significance of catechol amine phenotypic changes requires detailed knowledge about the sources and meanings of levels of DOPA, catecholamines, and catecholamine metabolites in hu man physiological fluids, such as plasma (Figs. 1 and 2, Table 1) , and knowledge about the chromosomal sites of genes encoding proteins participating in the synthesis, storage, release, metabolism, and recycling of catecholamines (Table 2 ).
GENETIC DISEASES W IT H S P E C IF IC CA T ECH O LA M IN ERG IC PHENOTYPES: SYNTHESIS
In mammals, catecholamine biosynthesis stems from a single enzymatic step-conversion of the amino acid tyrosine to the catechol amino acid l-DOPA by tyrosine hydroxylase (TH; EC 1.14.13.41; Fig. 1 ). Circulating catecholamines seem crucial for normal neurodevelopment, because genetic disorders of catecholamine biosynthesis typically produce severe neurological defects or fetal wastage. Thus, of mice with knockout of the TH gene, ~90% die in utero (Zhou et al., 1995) . Tyrosine hydroxylation requires tetrahydrobiopterin (BH4) as a cofactor. In humans, genetic deficiencies of BH4 synthesis or recycling, although compatible with survival to birth, obviate normal postnatal neuro logical development if not recognized and treated ap propriately from early infancy.
Dihydropteridine reductase (D H P R ) deficiency DHPR (EC 1.6.99.7) catalyzes the conversion of dihydrobiopterin to BH4. BH 4 is a required cofactor for hydroxylation not only of tyrosine but also of phenylala nine and tryptophan. BH4 also appears to play a role in maintaining the bioactive (tetrahydro) form of folic acid (Pollock and Kaufman, 1978) . Because of impaired phenylalanine hydroxylation, patients with DHPR defi ciency have a variant of phenylketonuria. In contrast to classical phenylketonuria (caused by specific mutations in the phenylalanine hydroxylase gene), where dietary restriction of phenylalanine beginning in infancy pro tects against mental retardation, patients with DHPR deficiency develop seizures and serious neurodevelopmental delays even with good dietary control of phenyl alanine intake (Kaufman et al., \915a, b) .
These clinical problems presumably arise from de ficient activities of TH and tryptophan hydroxylase and from defective folate metabolism. Corresponding biochemical consequences include the following : low CSF levels of metabolites of dopamine (DA) and nor epinephrine (NE) (Fig. 1) , such as DOPAC, HVA, DHPG, MHPG, and vanillylmandelic acid (VM A); low CSF levels of the serotonin metabolite 5-hydroxyindoleacetic acid; and low CSF levels of tetrahydrofolate (Niederwieser et al., 1985; Goldstein etal., 1995) . Therapy combining phenylalanine restriction with oral administration of l-DOPA, 5-hydroxy tryptophan (pre cursor of serotonin), and folinic acid appears to im prove neurodevelopmenta 1 outcomes in DHPR-deficient patients (Irons et al., 1987; Goldstein et al., 1995; Smooker et aL, 1995) .
At least 14 different mutations have been described at the DHPR locus (Matsubara et al,, 1992; Dianzani et al., 1993; Smooker et al., 1993 Smooker et al., , 1995 on chromo some 4 (Sumi et al., 1990) . Combinations of neurocheinical assessments with mutation detection or func tional characterization of abnormal DHPR alleles should help elucidate relationships between genotype and clinical phenotype in DHPR deficiency. Moreover, in a patient we studied , the pretreatment neurochemical findings (low but detectable plasma levels of DOPA and normal levels of NE, despite absent DHPR activity in erythrocytes and fi broblasts) led to the suggestion of a DHPR-independent mechanism for recycling BH4, illustrating how neurochemical analyses in patients with rare disorders can also enhance general understanding of catechol amine metabolism.
As suggested by the pathways in Fig. 2 , defects in GTP-cyclohydrolase I (EC 3.5.4.16) or 6-pyruvoyl tetrahydropterin synthase (no EC number listed) can also 5-CH3-H4-folate, 5-methyltetrahydrofolate; THF, tetrahydrofolate; q-BH2> quinonoid dihydrobiopterin; MTHFR, methyltetrahydrofolate reductase; DHPR, dthydropteridine reductase; BH4, tetrahydrobiopterin; Tyr, tyrosine; TH, tyrosine hydroxylase; COMT, catechol-Omethyltransferase; PST, phenylsulfotransferase; 3-MTyrosine, 3-methoxytyrosine; LAAAD, L-aromatic amino acid decarboxylase; D0PA-S04, l-DOPA sulfate; DA, dopamine; DA-SO4 , dopamine sulfate; MAO, monoamine oxidase; AD, aldehyde dehydrogenase; AR, aldehyde reductase; DBH, dopamine**/?-hydroxy!ase; NE, norepinephrine; 3-MT, 3-methoxytyramine; 3-MT-S04j 3-methoxytyramine sulfate; PNMT, phenylethanolamine-A/-methyltransferase; NMN, normetanephrine; EPI, epinephrine; MN, metanephrine; DHPG, dihydroxyphenylglycol; MHPG, methoxyhydroxyphenylglycol; EPI-S04, epinephrine sulfate; NMN-S04, normetanephrine sulfate; MN-S04, metanephrine sulfate; DHPG~S04, dihydroxyphenylglycol sulfate; MHPG-S04, methoxyhydroxyphenylglycol sulfate; VMA, vanillylmandelic acid; DOPAC, dlhydroxyphenylacetic acid; HVA, homovanillic acid.
produce atypical phenylketonuria due to defective B H 4 synthesis (Scrìver et al., 1996) . Complete deficiency of either enzyme leads to about the same clinical syn drome, with seizures, limb hypertonia, intermittent hy perthermia (Scriver et al., 1996) , and predictable asso ciated neurotransmitter abnormalities (Dhondt, 1984; Niederwieser et al., 1984) . Heterozygosity for mutation at the GTP-cyclohydrolase I locus produces DOPA-responsive dystonia, as discussed later. Deficiency of sepiapterin reductase (EC 1.1.1.153) or of carbinolamine dehydratase (no EC number listed), other enzymes in BH4 synthesis and recycling ( Fig. 1) should also produce predictable clinical and neurochemical abnormalities. As carbinolamine dehy dratase catalyzes a reaction that can also occur nonenzymatically, however, individuals with complete ab sence of this enzyme have mild clinical findings and only transient biochemical changes (Citron et al., 1993) . Examples of sepiapterin reductase deficiency have not been reported to date. Vitiligo Progressive depigmentation in vitiligo reflects nei ther a neurological nor a clearly inherited condition. This disorder, nevertheless, merits inclusion in this re view, because vitiligo patients may have localized, cell type-specific abnormalities of catecholamine biosyn thesis ( Schallreuter et aL, 1994) . Affected individuals have three-to fivefold increases in epidermal GTPcyclohydrolase I activity and decreased activity of carbinolamine dehydratase ( Schallreuter et al., 1994) . This combination increases formation of 7-BH4 (Fig.  2 ) , a by-product that potently inhibits phenylalanine hydroxylase (Adler et a l, 1992; Davis et al., 1992) . The genetic factors related to these alterations remain unknown.
Vitiligo patients have been reported to have in creased rates of urinary excretion of HVA and VMA, especially during the onset and in progressive active phases (Morrone et al., 1992) . Increased urinary ex cretion of norepinephrine has been noted in some af fected individuals (Schallreuter et al., 1994) . Data concerning plasma catecholamine levels have been in consistent (Orecchia et al., 1994; Schallreuter et al., 1994) , possibly due to a localized catecholaminergic abnormality. Additional genetic and neurochemical studies of patients with this disorder would be useful.
L-DOPA-responsive dystonia L-DOPA-responsive dystonia, which is inherited as an autosomal dominant trait, includes childhood-onset dystonia, abnormal gait, marked diurnal fluctuation (symptoms aggravated in the evening and alleviated in the morning after rest), concurrent or later develop ment of parkinsonism, and normal cognitive function. Oral l-DOPA treatment dramatically improves the neurologic symptoms.
It was the pattern of biochemical abnormalities in L-DOPA-responsive dystonia-low brain and CSF levels of DA, HVA, and BH4 (Nygaard, 1993; Nygaard et al., 1994; Rajput et al., 1994; Takahashi et al., 1994) -that led initially to the prediction that the dis order would be found to arise from deficient DA syn thesis due to decreased tyrosine hydroxylation. Genetic linkage analysis localized the putative mutant gene to chromosome 14q , but no candi date genes emerged from the genetic maps, until Ichinose and co-workers mapped the human GTP-cyclohydrolase gene to the L-DOPA-responsive dystonia criti cal region (Ichinose et ai., 1994) . The same workers demonstrated GTP-cyclohydrolase mutations in L-DOPA-responsive dystonia patients and documented severely reduced enzyme activity in affected patients. Numerous other GTP-cyclohydrolase mutations have since been reported in L-DOPA-responsive dystonia patients (Hirano et al., 1995; Furukawa et al., 1996) , including a splice junction defect that produces skip ping of exon 2 and predicts a truncated protein (Hirano et al., 1995) . Thus, the neurochemical abnormalities in L-DOPA-responsive dystonia not only fit the genetic J. Neitrochem., Vol. 67, No. 5, 1996 abnormalities identified so far but also predicted the type of genetic defect.
Whether an individual possesses one or two mutant GTP-cyclohydrolase alleles profoundly influences the resultant neurological phenotype. Comparisons of neu rochemical phenotypes in patients with autosomal re cessive GTP-cyclohydrolase deficiency (atypical phen ylketonuria) or autosomal dominant GTP-cyclohydro lase deficiency (L-DOPA-responsive dystonia) would be informative and potentially could provide insights about treatment possibilities.
L-Aromatic am ino acid decarboxylase (L A A A D ) deficiency LAAAD (EC 4.1.1.28) catalyzes the conversion of l-DOPA to DA (Fig. 1) and of 5-hydroxytryptophan to serotonin. The enzyme requires pyridoxal-5'-phos phate (vitamin B6). A case report describing twins with profound deficiency of this enzyme (Hyland et al., 1992) noted that the probands, products of a con sanguineous (first cousin) marriage, appeared normal at birth but developed slowly, with hypotonia and ab normal eye and limb movements by 2 months of age. A similarly affected older sibling had died when 9 months old. Both twins had low CSF and plasma levels of monoamines and high levels of DOPA and 5-hy droxytryptophan, from which the authors deduced the underlying enzymatic defect. As the parents each had intermediate LAAAD enzyme activity, the neurochem ical findings suggested heterozygosity for a mutant LAAAD allele. Treatment of the affected twins during infancy with pyridoxine, bromocriptine, and tranylcy promine produced some clinical benefit, although at 4 years of age neurodevelopment remained subnormal (Hyland et al., 1993) . Treatment commencing earlier in infancy might be more successful.
To our knowledge, the exact mutation in this, or any other, inherited form of LAAAD deficiency has not yet been defined. The human gene encoding LAAAD has been mapped to chromosome 7 (Craig et al., 1992; Scherer et al., 1992) and cloned. Two protein isoforms, resulting from alternative mRNA splicing, have been identified (O 'Malley et al., 1995) .
Dopamine-/?-hydroxylase (D B H ) deficiency
Although mutant mice lacking DBH (EC 1,14.17.1) die during fetal development (Thomas et al., 1995) , humans with absent DBH activity have surprisingly few neurological signs. Orthostatic hypotension invari ably occurs (Robertson et al., 1986) , associated with extremely low or absent concentrations of NE, DHPG, VMA, and MHPG and increased concentrations of DA, DOPAC, HVA, and l-DOPA (Goldstein et al., 1989) . The increase in plasma DOPA levels suggests compensatorily increased tyrosine hydroxylation in sympa thetic nerves (Goldstein et al., 1987) . Treatment with dihydroxyphenylserine, an amino acid converted to NE by decarboxylation, bypasses the enzymatic defect and produces remarkable clinical improvement in patients with DBH deficiency (Robertson et al., 1993) . Treat ment with dihydroxyphenylserine also rescues DBHdeficient mice (Thomas et al., 1995) .
As noted for LAAAD deficiency, no specific muta tions have been reported to date for patients with con genital absence of DBH. The lack of immunoreactive DBH in plasma or CSF (O ' Connor et al., 1994) sug gests that the underlying molecular defect may involve abnormal expression of the DBH gene, such as by a mutation affecting the DBH promoter, splice junctions, or coding sequence.
Menkes disease
Menkes disease is an X-linked recessive cause of infantile neurodegeneration that results from mutations in a gene encoding a copper-transporting ATPase (Chelly et a l, 1993; Mercer et al., 1993; Vulpe et al., 1993; Das et al., 1994) . Clinical features include seizures, severe developmental delay, failure to thrive, connective tissue abnormalities, such as bladder diver ticula and skin laxity, hair abnormalities ( ''pili torti" ), and death in infancy or early childhood (Kaler, 1994) . Other syndromes with less severe neurological pheno types (e.g., occipital horn syndrome) have also been associated with mutations at this locus . The clinical findings in Menkes disease and its variants result from reduced activities of coppercontaining proteins, such as ceruloplasmin, cyto chrome c oxidase, superoxide dismutase, lysyl oxidase, and DBH. Because the patients have impaired intesti nal copper absorption, serum copper levels are low after the first 2 months of life.
Decreased DBH activity in patients with Menkes disease causes a distinctive, abnormal pattern of plasma and CSF catechols (Kaler et al., 19936) , with high concentrations of DOPA, DOPAC, and DA, low concentrations of DHPG (an index of intraneuronal NE turnover), and approximately normal concentrations of NE itself, consistent with compensatory increases in sympathetic nerve traffic and tyrosine hydroxylation. The neurochemical pattern (in particular, elevated ra tios of DOPA/DHPG and DOPAC/DHPG) provides an excellent biochemical marker for this condition (Kaler et al., 1993Z?) . Thus, analyses of plasma levels of catechols can diagnose or exclude Menkes disease in at-risk infants during the newborn period, when clin ical signs are extremely subtle (Gunn et al., 1984) and other biochemical markers unreliable (Kaler et al., 1993a; Kaler, 1994) . The abnormal pattern can also be detected in umbilical cord blood of affected patients, indicating DBH deficiency in utero and suggesting that analysis of catechol levels in cord blood may constitute a rapid, noninvasive test for Menkes disease in at-risk newborns (Kaler et al., 1993a .
Early treatment with parenteral copper improves the clinical outcome in some patients with Menkes disease Turner et al., 1996) . The success of such therapy, however, appears to depend on the particular gene mutation (Kaler et al., 1995 Kaler, 1996) . Further analyses of clinical, biochemi cal, and molecular features should clarify the relative importance of mutation type and other factors in de termining the likelihood of response to treatment, and improved understanding of the copper transport pro cess mediated by the gene product and its homologues may facilitate development of novel therapies for this disorder. Correction of the abnormal neurochemical pattern could predict treatment efficacy.
Fam ilial dysautonomia
Familial dysautonomia, inherited as an autosomal recessive trait, produces a constellation of clinical findings that suggest deficient activities of multiple peripheral neurotransmitter systems, including catecholaminergic systems. Affected patients have neuro genic orthostatic hypotension, absent lingual papillae, no histamine-induced flare or overflow tears, and epi sodic paroxysmal hypertension, nausea, and vomiting. All familial dysautonomia patients identified to date have shared an Ashkenazic Jewish background, sug gesting that one or a few mutations account for the majority of cases. The responsible gene has not yet been reported but has been localized to chromosome 9q35 (Blumenfeld et ah, 1993) , a region close to the map location of the DBH gene (9q34).
Familial dysautonomia patients have high rates of excretion of HVA and low rates of excretion of VMA (Smith et al., 1963) . Although this pattern might sug gest deficient DBH activity, most of the patients have normal plasma DA and DOPAC levels. Familial dys autonomia patients have high plasma DOPA/DHPG ratios ( although less elevated than in Menkes disease patients), a failure to increase plasma NE levels during orthostasis [analogous to patients with acquired dysautonomias (Ziegler et aL, 1976 (Ziegler et aL, , 1977 ], and low plasma EPI levels (Axelrod et al., 1996) .
The plasma neurochemical pattern in familial dysau tonomia does not appear to fit any single abnormality of catecholamine synthesis, storage, reuptake, or me tabolism. Instead, the findings suggest more global ar rested differentiation of peripheral catecholamine sys tems during embryological development. Studies of nerve growth factor and its receptors have not been rewarding so far (Breakefield et al., 1984; Slaugenhaupt et al., 1995) . The phenotypic pattern, neverthe less, points to deficient innervation of the adrenal me dulla and other organs. Mechanisms by which the bound nerve growth factor receptor signals the cell bodies remain poorly understood; from the neurochem ical phenotype, one may speculate that the genetic ab normality involves a protein participating in these mechanisms. The DBH locus should be formally ex cluded .
G E N E T IC DISEASES W IT H SPE C IFIC C A T E C H O L A M IN E R G IC PHENOTYPES: M E T A B O LISM
Whereas catecholamine biosynthesis occurs mainly, if not exclusively, by a single pathway (tyrosine hydroxylation), catecholamine inactivation occurs by several alternative pathways that include at least three different intracellular enzymes (Fig. 1) . From this, and from the absolute requirement of BH4 for tyrosine hydroxylation, one might predict that, compared with the potentially devastating effect of mutations either in the TH gene itself or in genes encoding enzymes participating in synthesis or recycling of BH4, defects in genes encoding catecholamine-metabolizing en zymes would have less serious clinical consequences.
Mutations in genes that encode membrane catechol amine transporters or vesicular amine transporters (VATs) have not been reported, despite cloning of the genes and identification of their chromosomal loca tions (Table 2 ). A recent report described successful generation of mice with a knockout of the membrane DA transporter (Giros et al., 1996) . The animals had hyperlocomotion, decreased food intake, abnormal ma ternal behavior, and an increased likelihood of prema ture death. Neurochemically, the animals had de creased electrical stimulus-induced DA release and decreased tyrosine hydroxylation in dopaminergic neu rons. To our knowledge, no report to date has reported knockout or transgenic animals for the membrane NE transporter or for a VAT.
Monoamine oxidase (M A O ) deficiency MAO (EC 1.4.3.4) isoenzymes inactivate catechol amines and their 0-methylated metabolites (Fig. 1) and also deaminate other biogenic amines, such as se rotonin. The genes encoding the two subtypes of MAO (MAO-A and MAO-B) lie adjacent to each other on the X chromosome. Oxidative deamination of seroto nin depends on MAO-A; in vitro, both subtypes deami nate DOPA, DA, and NE.
Several inherited disorders involving MAO defi ciency have been described. A kindred of Dutch men with impulsivity, aggressiveness, and antisocial behav ior had isolated deficiency of MAO-A (Brunner et al., 1993/; ) , with a point mutation in exon 8 of the MAO-A gene (Brunner et al., 1993a) . The patients had in creased urinary excretion of NMN, HVA, and VMA.
Patients with Norrie disease, inherited as an Xlinked recessive trait, have blindness, deafness, and variable mental retardation. The Norrie disease gene is contiguous with the two MAO loci at Xpll.4-pl 1.3 (3,094, 3,075) , the order from centromere to telomere being Norrie disease/MAO-B/MAO-A. Norrie disease patients can have deletions that include the Norrie dis ease locus and either the MAO-B locus or both MAO loci (Lenders et al., 1996) . Two brothers with Norrie disease and selective MAO-B deficiency had minimal neurochemical alterations and no behavioral or psycho motor abnormalities. In contrast, a patient with deletion of all three loci had markedly increased levels of 0 -methylated amine metabolites and low levels of deaminated catecholamines, with severe mental deficiency, autistic-like behavior, atonic seizures, and altered pe ripheral autonomic function . These findings imply that MAO-A deficiency produces far more serious clinical consequences than does MAO-B deficiency. Some of these differences could depend on the importance of MAO-A in serotonin me tabolism, because mice exposed to MAO inhibitors in utero have increased aggressive behavior (Cases et al, 1995) mitigated by blockade of serotonin synthesis.
Pseudopheochromocytoma
Pheochromocytomas are adrenal tumors that synthe size and secrete catecholamines. The tumor, which usually is benign, typically presents as difficult-to-control hypertension, with paroxysms of severe high blood pressure, tachycardia, pallor, sweating, and headache. Because the tumor constitutes a rare, but curable, form of hypertension, hypertensive patients with these symptoms or signs often undergo diagnostic testing for pheochromocytoma. Kuchel and co-workers described a syndrome termed " pseudopheochromocytoma" (Kuchel et al., 1981 ) , in which the patients have clini cal findings consistent with pheochromocytoma, but instead of harboring the tumor, the patients have de creased plasma levels of conjugated catecholamines. Because sulfconjugation figures prominently in the in activation of circulating catecholamines [especially DA (Kuchel et aL, 1978; Ratge et al., 1991) ], these patients might have a deficiency of phenolsulfotransferase (PST; EC 2.8.2.1). Plasma levels of DA sulfate vary widely across individuals and species (Toth et al., 1986; Dousa and Tyce, 1988) , consistent with polymorphisms in the PST gene ( Aksoy and Weinshilboum, 1995) . Patients with complete deficiency of PST have not been described to date; the gene encoding PST was cloned recently (Aksoy et al., 1994; Aksoy and Weinshilboum, 1995) . The location is near the gene responsible for Batten disease, an autosomal re cessive disorder of lipofuscin metabolism (Taschner et al., 1995) .
Velo-cardio-facial syndrome and DiGeorge syndrome Velo-cardio-facial syndrome includes cleft palate, craniofacial abnormalities, learning disorders, cardiac defects, and psychiatric illness in adolescence and adulthood. DiGeorge syndrome includes immunodefi ciency, facial dysmorphism, mental disorders, and car diac defects. Both syndromes have been associated with interstitial deletions of chromosome 22q 11 Franke et al., 1994) . A study of nine families with recurrent cardiac outflow tract defects found that five had transmitted deletions of chromosome 2 2 qll . Chromo some 22q ll includes the locus of the gene encoding catechol-O-methyltransferase (COMT; EC 2.1.1.6). Thus, one may hypothesize that some patients with the velo-cardio-facial or DiGeorge syndrome may have only one functional COMT allele and decreased COMT activity (Dunham et al., 1992) . Abnormal ra tios of O-methylated to deaminated metabolites of cat echolamines in plasma or urine could detect this. The relationship between COMT activity and clinical fea tures of either syndrome remains unknown.
von Hippel-Lindau disease and pheochromocytoma von Hippel-Lindau disease is an autosomal domi nant disorder featuring hemangioblastomas, cystic tu mors, renal cell carcinomas, pancreatic cysts and tu mors, epididymal cystadenomas, and pheochromocytomas (Choyke et al., 1995) . von Hippel-Lindau dis ease patients with pheochromocytoma can have false negative results of screening tests based on plasma levels or urinary excretion of catecholamines or cate cholamine metabolites, and measurement of plasmafree (unconjugated) NMN and MN appears to provide a more sensitive biochemical marker (Lenders et al., 1995) . The von Hippel-Lindau disease gene, located on chromosome 3 (3p25), encodes a tumor supressor gene (Latif et al., 1993; Herman et al., 1994; Linehan et al., 1995) . Many mutations at different loci in this gene have been documented in individuals with the classic von Hippel-Lindau disease phenotype; how ever, familial pheochromocytoma seems to be associ ated with mutations at a specific locus (Crossey et aL, 1995; Gross et al., 1996; Neumann et al., 1996) .
CONCLUSIONS
The wealth of knowledge regarding the synthesis and fate of catecholamines, the availability of sensitive and specific assays for l-DOPA, catecholamines, and most of their metabolites, and recent advances in mo lecular genetics afford the opportunity to glean new understanding of neurogenetic disorders that involve catecholamine metabolism. This review has presented several examples rather than a comprehensive picture of this new application of clinical neurochemistry. The pathways outlined in Figs. 1 and 2 suggest the exis tence of several other genetic defects, as yet undiscov ered, with predictable neurochemical and clinical con sequences.
